Evaluation of Serum Ferritin, Creatinine, and Liver Enzymes in Patients with Beta-Thalassemia After Administration of Deferasirox
April 2023
in “
Tikrit Journal of Pharmaceutical Sciences
”
Studysummary In this study, researchers assessed the effects of deferasirox in 85 children with ß-thalassemia in Kirkuk and reported that while 55.3% experienced a reduction in serum ferritin, 9.4% had adverse effects, indicating that deferasirox is generally well-tolerated as an iron chelator with modifiable side effects.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The study on 85 patients with ß-thalassemia in Kirkuk, Iraq, found that deferasirox, an oral iron chelator, effectively reduced serum ferritin levels in 55.3% of patients, indicating a decrease in iron overload. Some adverse effects were observed, including elevated serum creatinine in 25.8% of patients, elevated liver enzymes, and hair loss in 2 patients. Despite these side effects, deferasirox was generally well-tolerated, and its adverse effects could be managed by adjusting the dosage. The study concludes that deferasirox is a suitable treatment for managing iron overload in ß-thalassemia patients.
